COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04540484 |
Recruitment Status :
Recruiting
First Posted : September 7, 2020
Last Update Posted : September 9, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Covid19 SARS-CoV Infection Communicable Disease |
Study Type : | Observational |
Estimated Enrollment : | 900 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | The Prevalence of SARS-CoV-2 IgG Antibody Formation in Physicians at Advocate Lutheran General Hospital and Their Household Members |
Actual Study Start Date : | August 26, 2020 |
Estimated Primary Completion Date : | September 24, 2021 |
Estimated Study Completion Date : | September 24, 2021 |

Group/Cohort |
---|
ALGH Physicians
Attending physicians on the medical staff, fellow physicians, and resident physicians that work at Advocate Lutheran General Hospital (ALGH) from March 1st, 2020 and forward.
|
Household Members
Household members above age 18 who lived in household of ALGH physician who tested positive for COVID-19 IgG antibodies, and who lived with that physician for at least 2 consecutive weeks.
|
- Identifying positive COVID-19 IgG formation [ Time Frame: up to 1 year ]
- Physician Prevalence of COVID-19 serum IgG [ Time Frame: up to 1 year ]The prevalence of COVID-19 serum IgG in physician participants at study entry, 3 months, 6 months, and 12 months after enrollment.
- Household Member Prevalence of COVID-19 serum IgG [ Time Frame: up to 1 year ]The prevalence of COVID-19 serum IgG in household members (as defined above) of physician participants that are positive at the time the associated physician tested positive.
- Physician Risk of Exposure [ Time Frame: up to 1 year ]The differences in prevalence of COVID-19 IgG in physician participants that are deemed to be at minimum, moderate or high risk of COVID-19 exposure.
- Physician and Household Member Transmission [ Time Frame: up to 1 year ]The differences in prevalence of COVID-19 IgG in household members of physician participants that are positive for COVID-19 IgG.
- Asymptomatic Infection [ Time Frame: 1 year ]The correlation between IgG prevalence and previous COVID-19 symptoms - a means of quantifying the presence of asymptomatic carriers amongst the medical staff, an important and heretofore poorly described vector of transmission.
- PPE Use and Positivity [ Time Frame: up to 1 year ]The correlation between the prevalence of seropositivity and adherence to best practices regarding the use of personal protective equipment.
- Antibody Persistence [ Time Frame: up to 1 year ]The development of COVID19 infections in physicians at our hospital over the test period of 12 months, and its correlation to Covid19_IgG positivity. This will allow us to understand the persistence of the antibody and its potential neutralizing power, over time.
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Attending physician staff members, fellow physicians, and resident house staff members who were on staff at ALGH from March 1st, 2020 and on, with potential exposure to COVID-19 patients.
- A maximum of two adult household members as defined as, any person over the age of 18 years old who has lived at home with the physician for at least 2 weeks in total duration since March 1st, 2020. Any adult household member of attending physicians on the medical staff, fellow physicians, and resident physicians may qualify as long as the tested physician resulted positive for IgG Antibodies to COVID-19. The adult household member will be selected by the household physician based on their assessment of risk of also testing positive.
- Must be willing to undergo venipuncture, sign consent and complete the questionnaire. Participants need to speak, read, and understand English at the literacy level of a 8th grader.
- Those with a prior documented COVID-19 infection are eligible for study inclusion. We will rely on self-reporting by physicians due to the fact that the data from the other study conducted in the Advocate Aurora System has been de-identified and we cannot access the results on individual participants in our study.
Exclusion Criteria:
- Healthcare providers and/or their household members who would not want venipuncture performed on them
- Healthcare workers who are not on the medical staff or members of the resident house staff

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04540484
Contact: Sigrun Hallmeyer, MD | 8479717662 | sigrun.hallmeyer@aah.org |
United States, Illinois | |
Advocate Lutheran General Hospital | Recruiting |
Park Ridge, Illinois, United States, 60068 | |
Contact: Katie Wozniak 847-723-2300 katie.wozniak@aah.org | |
Principal Investigator: Sigrun Hallmeyer, MD |
Responsible Party: | Sigrun Hallmeyer, MD, Medical Director, ALGH Cancer Service line & Medical Direct, Cancer Survivorship Center, Advocate Health Care |
ClinicalTrials.gov Identifier: | NCT04540484 |
Other Study ID Numbers: |
1606472-1 M5500436 ( Other Identifier: ALGH ) |
First Posted: | September 7, 2020 Key Record Dates |
Last Update Posted: | September 9, 2020 |
Last Verified: | September 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID19 IgG Testing COVID-19 Antibodies |
Communicable Diseases Infection Coronavirus Infections Severe Acute Respiratory Syndrome Coronaviridae Infections |
Nidovirales Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |